Indian Pharmaceutical Market Outlook - Enhanced Purchasing Power, Rural Market Penetration And Expanded Access To Healthcare Attracting Big Pharma Investment
NEW YORK, Jan. 29, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p01089005/Indian-Pharmaceutical-Market-Outlook---Enhanced-purchasing-power-rural-market-penetration-and-expanded-access-to-healthcare-attracting-Big-Pharma-investment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=PharmaceuticalIndian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment Summary GBI Research's new report "Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment" provides in-depth analysis of the trends, issues and challenges facing the Indian pharmaceutical market. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The Indian pharmaceutical industry grew from $0.8 billion in 1980 to $21.73 billion in 2010 and is expected to grow further as Multinational Companies (MNCs) enter the market. Although pharmaceutical giants such as GlaxoSmithKline (GSK) have been present in the market for years, the rising income of the middle-class population, changing patent laws, low-cost skilled labor and low-priced infrastructure in India have attracted other MNCs. With the current scenario, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 12% during the 2011–2015 period. Branded generics are expected to become more prevalent in India as many global players are planning to launch them after their patents expire. The once highly fragmented Indian pharmaceutical industry is undergoing strategic consolidations with the aim of emerging as a highly organized sector. With the inflow of MNCs' R&D operations the industry will continue to experience a trend of M&A. Deals and acquisitions are set to continue due to low-cost infrastructure and labor as patent expiries and the thin pipelines of major companies will cause revenues to fall.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts